Figure 2

Anti-vascular endothelial growth factor therapy reduced microaneurysm formation, leading to good visual prognosis in branch retinal vein occlusion.

Patients, Sub-Tenon’s capsule injection of triamcinolone acetonide (Triamcinolone): Twenty eyes of 20 patients (9 men, 11 women). Anti-VEGF therapy: Twenty-two eyes of 22 patients (13 men, 9 women). Switch from triamcinolone to anti-VEGF therapy: Sixteen eyes of 16 patients (7 men, 9 women). (A) The number of microaneurysms after each treatment. The panels in the top row are representative images from each treatment group. Anti-vascular endothelial growth factor (VEGF) therapy significantly (P < 0.01) reduced microaneurysms formation compared with the Triamcinolone group. Error bars represent the standard error of the mean above or below. NS, not significant. (B) Changes in the logarithm of minimal angle of resolution (logMAR) visual acuity (VA) in each treatment group. Anti-VEGF therapy significantly improved the log MAR VA, while triamcinolone or switch therapy did not do so. (C) Changes in central retinal thickness (CRT) with each treatment. The CRT significantly (P < 0.01) decreased with all treatments at the final visit. Only the anti-VEGF therapy significantly (P < 0.01) reduced the CRT at year 1. The number of injections: Triamcinolone 2.4 ± 2.2, anti-VEGF 5.2 ± 2.4, switch from triamcinolone to anti-VEGF 2.4 ± 2.0 (triamcinolone) and 3.4 ± 2.3 (anti-VEGF) (mean ± standard deviation).